Cardiometabolic and antineoplastic potential of sodium-glucose cotransporter type 2 inhibitors (iSGLT2) [Potencial cardiometabólico y antineoplásico de los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2)]
DOI:
https://doi.org/10.62574/8q2gm469Keywords:
heart failure, type 2 diabetes mellitus, cardiotoxicityAbstract
Objective: to analyse the cardiometabolic and antineoplastic potential of sodium-glucose cotransporter type 2 inhibitors (SGLT2 inhibitors). Method: systematic review. Results and conclusion: Sodium-glucose cotransporter type 2 inhibitors have demonstrated robust cardioprotective effects in patients with heart failure, particularly those with reduced ejection fraction. The mechanisms include haemodynamic, antioxidant, anti-inflammatory and renoprotective effects that transcend glycaemic control.
Downloads
References
Levette JAN, Leal FJV, Daza OPR, Anturi YC, Hernandez FAT, Masi AJB, et al. Efecto cardioprotector de los inhibidores de SGLT2 y agonistas del receptor de GLP-1. Ciencia Latina Revista Científica Multidisciplinar. 2022 Ago 29;6(4):2497-511.
Vargas Delgado AP, Requena Ibañez JA, Santos-Gallego CG, Badimon JJ. ¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares? Clínica e Investigación en Arteriosclerosis. 2021 Ene 1;33(1):33-40.
Buitrago Sandoval AF, Sánchez Vallejo CA. Mecanismos de acción de los inhibidores de cotransportador de sodio y glucosa tipo 2 —SGLT2—: Más allá del control de la glicemia. Rev Colomb Cardiol. 2020 Mar;27:22-5.
Castillo LFA, Ruiz KPC, Espinoza JAM. Rol de los inhibidores de SGLT2 en pacientes con comorbilidad cardiovascular, renal, hematológica y su implementación a nivel institucional en Costa Rica. Rev Ciencia y Salud Integrando Conocimientos. 2024 Dic 20;8(3):101-8.
Herrera Valdera G, Hoyos Gallardo A. Beneficios de los inhibidores de SGLT2 en pacientes con diabetes mellitus tipo 2 [Internet]. [citado 2025 Mar 19]. Disponible en: https://repositorio.uss.edu.pe/bitstream/handle/20.500.12802/13827/Herrera%20Valdera%20Gustavo%20%26%20Hoyos%20Gallardo%20Angy.pdf?sequence=1&isAllowed=y.
Gómez LS, Negrete JPG. Evidencia molecular y clínica del beneficio cardiovascular de los inhibidores SGLT2: estado del arte. Medicina UPB. 2022 Ago 8;41(2):145-56.
Pittampalli S, Upadyayula S, Mekala HM, Lippmann S. Risks vs benefits for SGLT2 inhibitor medications. Fed Pract. 2018 Jul;35(7):45-8.
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits | Cardiovascular Research | Oxford Academic [Internet]. [citado 2025 Mar 19]. Disponible en: https://academic.oup.com/cardiovascres/article/120/5/443/7624376.
Garmendia CM. Beneficio de los inhibidores de SGLT2 en pacientes con cáncer y diabetes mellitus [Internet]. MedEcs. 2022 [citado 2025 Mar 19]. Disponible en: https://medecs.com.ar/beneficio-de-los-inhibidores-de-sglt2-en-pacientes-con-cancer-y-diabetes-mellitus/.
Naeimzadeh Y, Tajbakhsh A, Nemati M, Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur J Pharmacol. 2024 Sep 5;978:176803.
Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, et al. Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2021;23(8):1260-75.
Fuchs Andersen C, Omar M, Glenthøj A, El Fassi D, Møller HJ, Lindholm Kurtzhals JA, et al. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail. 2023 Feb;25(2):226-34.
Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, et al. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. Clin Res Cardiol. 2023;112(1):134-44.
Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. J Am Coll Cardiol. 2024 Abr 16;83(15):1386-98.
Veerni R, Bhalraam U, Paddock S, Meng J, Vassiliou V, Tsampasian V. Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in cancer patients: a systematic review and meta-analysis of heart failure hospitalisation and mortality. Epistemonikos. 2024 [citado 2025 Mar 18]. Disponible en: https://www.epistemonikos.org/en/documents/1b14d7d225e1ef32712080f58e11ae0ac771b17c.
Maragoudakis S, Marketou M, Sideras M, Vittorakis E, Mavroudeas SE, Emiri F, et al. The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients. Eur Heart J. 2023 Nov 9;44(Suppl_2):ehad655.2716.
Gongora CA, Drobni ZD, Silva TQAC, Zafar A, Gong J, Zlotoff DA, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022 Ago;10(8):559-67.
Osataphan N, Abdel-Qadir H, Zebrowska AM, Borowiec A. Sodium-glucose cotransporter 2 inhibitors during cancer therapy: benefits, risks, and ongoing clinical trials. Curr Oncol Rep. 2024;26(10):1188-96.
Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy–related cardiac dysfunction. JACC Heart Fail. 2024 Ene 1;12(1):67-78.
Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024 Abr 1;6(2):159-82.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 María Gabriela Balarezo-García, Diego Armando Suárez-Páez, Yesenia Esthefanía Arellano-Oleas, Daniel Mateo Toro-Bautista (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
